RIM
ONCT

Reliant Investment Management’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Reliant Investment Management’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q4 		– Sell
-15
Closed -$16K – 64
2014
Q3 		$16K Buy
+15
New +$22.1K 0.01% 59
2014
Q2 		– Sell
-15
Closed -$33K – 68
2014
Q1 		$33K Hold
15
– – 0.03% 63
2013
Q4 		$36K Buy
+15
New +$34.3K 0.03% 66

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Reliant Investment Management's ONCT Position: Q4 2014 in Review

Reliant Investment Management sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q4 2014, closing a stake of 15 shares — an estimated $16K sold.

Reliant Investment Management first reported a position in ONCT in Q4 2013 and held it in 3 quarters. The position peaked at $36K in Q4 2013. 40 funds tracked by Wall St. Rank hold ONCT as of Q4 2014.

  • Reliant Investment Management reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
  • Reliant Investment Management sold 15 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $16K.
  • Reliant Investment Management first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2013 and held it in 3 quarters.
  • Reliant Investment Management's Oncternal Therapeutics, Inc. Common Stock position peaked at $36K in Q4 2013.
  • 40 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2014.

Based on Reliant Investment Management's 13F filing for Q4 2014, filed 17 Feb 2015.